ProCE Banner Activity

HER3-Targeted Antibody–Drug Conjugates for Lung and Breast Cancers: Where We Are Today

Clinical Thought

Get the latest expert insights on current HER3-directed antibody–drug conjugates used in the treatment of breast and lung cancer.

Released: September 29, 2023

Share

Faculty

Helena Yu

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Yuan Yuan

Yuan Yuan, MD, PhD

Director, Breast Oncology
Cedars-Sinai Medical Center
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.

Disclosure

Primary Author

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Helena Yu, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Black Diamond, Daiichi Sankyo, Janssen, Taiho, Takeda; researcher: AstraZeneca, Black Diamond, Daiichi Sankyo, Cullinan, ERASCA, Janssen, Novartis, Pfizer.

Yuan Yuan, MD, PhD

Director, Breast Oncology
Cedars-Sinai Medical Center
Los Angeles, California

Yuan Yuan, MD, PhD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Gilead, Merck; researcher: Merck.